The daraxonrasib FDA approval, granted on 26 August 2026, gives metastatic pancreatic cancer its first approved targeted therapy. Revolution Medicines will sell the drug as Rasonque. The agency cleared it roughly six and a half months ahead of its goal date. For an industry accustomed to year-long reviews, that timeline carries almost as much weight as the clinical data.
Pancreatic ductal adenocarcinoma has resisted targeted therapy for decades. Oncogenic RAS mutations are present in more than 90 per cent of cases. That figure comes from the New England Journal of Medicine. Until recently, the protein was widely considered undruggable. This decision closes that chapter and opens a harder commercial question for European buyers.
What the daraxonrasib FDA approval covers
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma. The label covers patients who have received at least one prior systemic therapy. It also covers those who are not candidates for multiagent systemic therapy.
The recommended dose is 300 mg orally once daily. Treatment continues until disease progression or unacceptable toxicity. Daraxonrasib is a RAS(ON) multi-selective, noncovalent tri-complex inhibitor. It targets the active, GTP-bound form of RAS rather than a single mutant variant.
That mechanism matters commercially. Earlier RAS drugs addressed narrow mutation subsets. The label requires no companion diagnostic test. It covers patients with or without an identified tumour RAS mutation. That is what expands the eligible population, and it removes a testing step before prescribing.
The RASolute 302 data behind the daraxonrasib FDA approval
Approval rested on the Phase 3 RASolute 302 trial, registered as NCT06625320. The global, randomised, open-label, multicentre trial randomised 500 patients. Participants received either daraxonrasib or physician-selected standard chemotherapy. Primary endpoints were overall survival and progression-free survival in the RAS G12 mutant population.
Survival and response endpoints
In the intent-to-treat population, median overall survival reached 13.2 months on daraxonrasib. The chemotherapy arm recorded 6.7 months. The hazard ratio was 0.40, with a 95 per cent confidence interval of 0.30 to 0.53. The p value fell below 0.0001. That represents a 60 per cent reduction in the risk of death. Overall survival in that population was a key secondary endpoint.
Median progression-free survival in the same population was 7.2 months against 3.6 months. The hazard ratio here was 0.49, with a confidence interval of 0.38 to 0.64. Objective response rate reached 30 per cent versus 11 per cent on the FDA label. The journal publication and the trial centre reported marginally higher figures of 31.6 and 11.2 per cent. LSDN cites the label values throughout for consistency.
Quality-of-life measures moved in the same direction. Median time to deterioration in global health status was 5.7 months on daraxonrasib. Chemotherapy patients reached that point at 2.6 months. Time to pain deterioration extended to 9.2 months against 3.8 months.
The primary endpoint population was patients with RAS G12 mutations. In that group, one-year survival reached 53.3 per cent. The comparator arm recorded 18.7 per cent at the same timepoint. Median overall survival there was 13.2 months against 6.6 months. The full dataset appeared in the New England Journal of Medicine.
Safety and tolerability
Toxicity was frequent but largely manageable. Dermatologic toxicity affected 86 per cent of treated patients, 10 per cent at Grade 3. Diarrhoea occurred in 63 per cent and stomatitis in 57 per cent. Serious adverse events were recorded in 30 per cent.
Grade 3 or higher treatment-related events reached 43.6 per cent on daraxonrasib. The chemotherapy arm recorded 57.5 per cent. Discontinuation because of treatment-related adverse events ran at 1.2 per cent against 11.2 per cent. The label separately reports all-cause discontinuation at 2.9 per cent.
The label carries warnings for dermatologic and soft tissue toxicity, stomatitis and diarrhoea. It also flags gastrointestinal perforation, interstitial lung disease and embryo-foetal toxicity. Oncology pharmacy teams will need dermatological support pathways in place before launch.
How the voucher pathway shaped the daraxonrasib FDA approval
The company confirmed that the FDA accepted its application on 22 July 2026. Approval followed on 26 August. The application itself was a rolling submission, largely complete by early July. Daraxonrasib was selected for the FDA Commissioner’s National Priority Voucher pilot programme. That scheme aims to accelerate review of medicines addressing national health priorities.
The drug also held Breakthrough Therapy and Orphan Drug designations. It was included in Project Orbis, the FDA’s concurrent oncology review framework. The agency also used its Real-Time Oncology Review pilot and the Assessment Aid. Both streamlined data submission before the full clinical application was filed. The FDA says it approved the drug about 6.5 months ahead of its goal date. LSDN reported on the filing strategy when the rolling submission neared completion in July.
Regulatory affairs teams should read the outcome carefully. The 35 day interval broadly matches what the voucher pilot was designed to deliver. Its stated target is one to two months from filing to action. The scheme itself remains contested, because vouchers are awarded at the Commissioner’s discretion rather than by fixed criteria. Whether the timeline generalises will depend on how many vouchers are issued.
What the daraxonrasib FDA approval means for UK access
The daraxonrasib FDA approval does not translate into British prescriptions. Two separate processes now determine European availability.
The EMA phased review
Revolution Medicines announced on 7 July 2026 that the European Medicines Agency had begun a phased review. Its human medicines committee is assessing quality, nonclinical and clinical data in stages. That work is proceeding ahead of a complete marketing authorisation application.
The agency states that a phased review “aims to accelerate the assessment of a medicine”. It does so, in the EMA’s words, “by evaluating the data in phases as they become available”. The agency has declined to forecast a completion date. The EMA does expect the process to run shorter than a regular evaluation.
The MHRA recognition route
British availability will most likely run through the International Recognition Procedure. The MHRA recognises seven reference regulators under that framework, including the FDA. Route A carries a 60 day assessment timetable. Route B extends to 110 days and includes a clock stop.
Regulatory analysts expect dossiers from non-EMA reference regulators to route more often to Route B. An FDA-led daraxonrasib application would likely follow that pattern. Recognition is not automatic, and the MHRA retains full discretion to refuse.
Reimbursement is a separate hurdle. NICE has been explicit that its evidence requirements remain unchanged regardless of the regulatory approval route. Market access teams should therefore plan appraisal submissions independently of the recognition timetable.
Why the UK burden makes this urgent
Pancreatic Cancer UK recorded 10,787 diagnoses a year between 2017 and 2019. Deaths averaged 9,558 annually over the same period. The disease ranks as the fifth biggest cancer killer in the country.
Roughly 80 per cent of patients are diagnosed at stage three or four. Five-year survival sits below 7 per cent nationally. Any therapy that nearly doubles median survival in advanced disease will attract intense clinical scrutiny.
Clinical reaction and pipeline read-through
Brian M. Wolpin led RASolute 302 as principal investigator. He directs the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute. He called the approval “a landmark advance for patients with metastatic pancreatic cancer”. Revolution Medicines funded the trial, and Wolpin discloses a financial relationship with the company.
Wolpin noted that researchers had long believed RAS could be targeted successfully. Blocking RAS signalling therapeutically, he said, “proved extraordinarily challenging”. He described the survival gain as “meaningful progress for patients where new treatment options are urgently needed”.
Benjamin L. Ebert is president and chief executive of Dana-Farber Cancer Institute. He called the decision “an important milestone for patients with pancreatic cancer”. Mark A. Goldsmith, chief executive and chairman of Revolution Medicines, described it as “a monumental step forward for patients”.
Rachna T. Shroff is chief of the division of haematology and oncology at the University of Arizona. She is based at its College of Medicine in Tucson. Speaking at an ASCO press briefing as an ASCO Expert, she called the study “incredibly impactful”. Doubled survival in previously treated patients, she said, had not been seen before.
Anna Berkenblit is chief scientific and medical officer at the Pancreatic Cancer Action Network. In the company’s own announcement she called the approval “the most significant advance” seen against the disease. Patient organisations on both sides of the Atlantic will now press for rapid local availability.
Two further Phase 3 studies remain in progress. RASolute 303 evaluates first-line use, alone and with chemotherapy. RASolute 304 treats resected patients after standard adjuvant chemotherapy. Positive readouts in either would expand the addressable population sharply.
What to watch next
The daraxonrasib FDA approval creates three near-term signals for the sector. First, watch whether the EMA phased review completes materially faster than a standard assessment. Second, watch whether Revolution Medicines files through the MHRA recognition route promptly. Third, watch how NICE handles a therapy with strong survival data and a high list price.
Revolution Medicines set a US list price of $39,800 for a 30-day supply. That works out near $478,000 a year before discounts. The figure, not the efficacy data, will shape the reimbursement debate. Eligible insured US patients may pay as little as $0 through the company’s (ON)Path support programme. No equivalent scheme has been announced for Europe. LSDN tracks pending decisions in its regular FDA approvals monitor.
For competitors in the RAS field, the daraxonrasib FDA approval resets the benchmark. Rivals must now show comparable survival gains against a licensed targeted agent, not against chemotherapy alone. That is a materially harder trial to design.
